K-Ras mutation testing is now mandated by the regulatory authorities in the United States and in Europe (Allegra et al, 2009; van Krieken and Tol, 2009) and is routinely used as a patient selection biomarker for cetuximab prescription in colorectal cancer patients. This evidence concerns the gene KRAS and colorectal cancer.